ERISNSEEris Lifesciences LimitedMinimalNeutral
Announced Wed, 27 May · 14:47 IST

Eris Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹1361.70
prior close
₹1352.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.0-0.1-0.1+2.4+1.4+0.0+2.4+0.5+0.7+4.8+2.9+3.8
Up moveDown movePending
AI summary

Promoter Kaushal K. Shah has submitted the annual declaration confirming the promoter and promoter group collectively hold 7,47,08,744 equity shares, representing approximately 53.92% of the total equity capital of Eris Lifesciences Limited as on March 31, 2026. The disclosure is made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing also confirms that no encumbrances (pledging or creating charges on shares) have been created during the financial year, other than those already disclosed earlier.

Likely market impact

Promoters maintaining over 53% stake with no additional encumbrances signals stability in the promoter group's holding, which is reassuring for minority shareholders as it reduces risk of forced selling or dilution.